Described herein are flash nanoprecipitation methods capable of encapsulating hydrophobic molecules, hydrophilic molecules, bioactive protein therapeutics, or other target molecules in amphiphilic copolymer nanocarriers.

The present invention relates to a drug delivery system at least comprising a drug encapsulated in a polymeric nano vesicle (polymersome), wherein the drug component is an anthracycline derivative according to the formula I wherein R.sup.1 is selected from the group consisting of H, F, —OMe or —OEt; R.sup.2 is selected from the group consisting of H, —OMe, methyl or ethyl; R.sup.3 is selected from the group consisting of H, methyl or ethyl, and R.sup.4 is H or a protecting group; the polymersome is formed by polymers comprising PEG, PEA, PCL, PTMC or PTMB building blocks or combinations thereof, wherein the polymersome polymers are, at least in part, functionalized by chemically attaching via a linker group L a targeting moiety, wherein the targeting moiety is selected from the group consisting of antibodies, peptides, aptamers or mixtures thereof. In addition, the present invention relates to process for the production of an anthracycline derivative loaded, targeted polymersome drug delivery system, a pharmaceutical composition comprising said drug delivery system and the use of said pharmaceutical composition for the treatment of cancer.

This invention provides a long-lasting artificial cell membrane with a prefabricated, freestanding biopolymer hydrogel as the cytoskeleton that is partially tethered to and supports lipid bilayer for high stability. The highly stable lipid bilayer has unrestricted fluidic, optical and electrical accesses to both sides of the lipid bilayer, which has significant impact on fundamental biological studies and advanced pharmaceutical industries.

The present invention provides novel nanostructures comprising solution of PPSU.sub.20. Methods of preparing the novel PPSU nanostructures, and applications of such nanostructures are also provided.

A drug-loaded polymer vesicle having an asymmetric membrane structure, a preparation method therefor, and an application thereof in preparation of drugs for treating acute myeloid leukemia. An amphiphilic triblock polymer having polyaspartic acid (PAsp), a targeted amphiphilic block polymer, and a small-molecule drug are assembled together to prepare the targeted small-molecule drug-loaded polymer vesicle having the asymmetric membrane structure. The drug-loaded polymer vesicle has many unique advantages, comprising small size, simple and controllable preparation, reversible crosslinking, in-vivo stability, targeted delivery, high enrichment concentration of intracellular drugs, reduction sensitivity, efficient killing of tumor cells, remarkable tumor growth inhibition effect, etc., and has an effective inhibition effect on both acute myelogenous leukemia cell strains and patient cells. Therefore, the polymer vesicle is expected to become a simple and multifunctional nanoplatform for efficient and specific targeted delivery of the drugs to the tumor cells.

The present disclosure provides LNPs comprising payload molecules, e.g., mRNA therapeutics, for the treatment of diseases or disorders, which would benefit from delivery of payload molecules to airway cells.

A polymeric compound is disclosed herein, having the general formula I:

##STR00001##

wherein m, n, X, Y, Z and L are as defined herein. Further disclosed herein are lipid bilayers comprising at least one bilayer-forming lipid and the aforementioned polymeric compound, and liposomes comprising such a bilayer, as well as methods, uses and compositions utilizing such bilayers and/or liposomes for reducing a friction coefficient of a surface and/or for inhibiting biofilm formation.

The present application is related to a pharmaceutical composition a biphasic lipid vesicle comprising a lipid bilayer comprising vesicle forming lipids; an oil-in-water emulsion stabilized by one or more surfactants; one or more compounds; and one or more penetration enhancing agents. The one or more penetration enhancing agents include one or more non-ionic surfactants having a hydrophilic-lipophilic balance (HLB) of about 10 or less, alone or combination with one or more penetration enhancing agents selected from one or more of terpenes, alkaloids, salicylate derivatives, and polycationic surfactants and combinations thereof. The present application is also related to a pharmaceutical composition comprising a biphasic lipid vesicle comprising a lipid bilayer comprising vesicle forming lipids; an oil-in-water emulsion stabilized by one or more polycationic surfactants; and one or more compounds.

Therapeutic compositions, comprising: an anti-reactive oxygen species agent and a pervious polymersome, the pervious polymersome encapsulating the anti-reactive oxygen species agent, and the pervious polymersome having therein channels defined by a channel diblock copolymer, the channels being arranged so as to retain at least some of the anti-reactive oxygen species agent within the pervious polymersome while allowing reactive oxygen species to pass into the pervious polymersome.

Method of treating a patient, comprising: administering an effective amount of a therapeutic composition, the therapeutic composition comprising an anti-reactive oxygen species agent disposed within a pervious polymersome, the pervious polymersome encapsulating the anti-reactive oxygen species agent, and the pervious polymersome having therein channels defined by a channel diblock copolymer, the channels being arranged so as to retain at least some of the anti-reactive oxygen species agent within the pervious polymersome while allowing reactive oxygen species to pass into the pervious polymersome.

Phospholipid-polymer-aromatic conjugates comprising binding ligands, liposome compositions including the phospholipid-polymer-aromatic conjugates, and binding ligands having an affinity for misfolded proteins are described. The phospholipid-polymer-aromatic conjugate may be represented by Structural Formula I: PL-AL-HP-X-BL (I). In Formula I, PL is a phospholipid, AL is an aliphatic linkage, HP is hydrophilic polymer, X is a link between the phospholipid-polymer and the binding ligand, and BL is polycyclic aromatic compound that functions as a binding ligand. The liposomal compositions may be useful for the imaging of misfolded and/or aggregated proteins.